Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12798508 | 0.92 | CYP1A2 (0.39) | CYP1A2HIF1ACHRM2CHRM4CHRM3 | |
| SCHEMBL13882832 | 0.91 | CYP1A2 (0.46) | CYP1A2HIF1ABRD4SMN1; SMN2PPM1B | |
| SCHEMBL3310290 | 0.88 | CYP1A2 (0.39) | CYP1A2HIF1ACHRM2CHRM4CHRM3 | |
| SCHEMBL11782843 | 0.86 | CYP1A2 (0.38) | CYP1A2HIF1ACHRM2CHRM4CHRM3 | |
| SCHEMBL3362070 | 0.82 | CYP1A2 (0.38) | CYP1A2HIF1ACHRM2CHRM4CHRM3 | |
| SCHEMBL30052789 | 0.80 | BRD4 (0.36) | CYP1A2HIF1ACHRM2CHRM4CHRM3 | |
| SCHEMBL5346726 | 0.78 | CYP1A2 (0.41) | CYP1A2HIF1ABRD4PPM1BPTPN1 | |
| SCHEMBL374935 | 0.78 | MAPK1 (0.47) | CYP1A2HIF1AMAPK1THRBTLR4 | |
| SCHEMBL31276435 | 0.78 | MAPK1 (0.47) | CYP1A2HIF1AMAPK1THRBTLR4 | |
| SCHEMBL25061 | 0.78 | MAPK1 (0.47) | CYP1A2HIF1AMAPK1THRBTLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4303277-A1 | ANTIFOULING COATING COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022186143-A1 | ANTIFOULING COATING COMPOSITION | 日東化成株式会社 | 2022-09-09 | — | — | WO | disclosed |
| US-9029537-B2 | Electroluminescent materials | LOMOX LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-9029537-B2 | Electroluminescent materials | LOMOX LIMITED (GB) | 2015-05-12 | — | — | US | disclosed |
| US-8558013-B2 | Electroluminescent materials | LOMOX LIMITED (GB) | 2013-10-15 | — | — | US | disclosed |
| US-8558013-B2 | Electroluminescent materials | LOMOX LIMITED (GB) | 2013-10-15 | — | — | US | disclosed |
| US-20130037752-A1 | ELECTROLUMINESCENT MATERIALS COMPRISING FLUORENE DERIVATIVES | LOMOX LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130037752-A1 | ELECTROLUMINESCENT MATERIALS COMPRISING FLUORENE DERIVATIVES | LOMOX LIMITED (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20110015404-A1 | Electroluminescent Materials | LOMOX LIMITED (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20110015404-A1 | Electroluminescent Materials | LOMOX LIMITED (GB) | 2011-01-20 | — | — | US | disclosed |
| WO-2009049018-A1 | NOVEL COMPOUNDS AND METHODS OF USING THEM | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049018-A1 | NOVEL COMPOUNDS AND METHODS OF USING THEM | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130037752-A1 | ELECTROLUMINESCENT MATERIALS COMPRISING FLUORENE DERIVATIVES | SPIN2B, FLNB, LMNB2 | CYP1A2 1756/4885HIF1A 4686/4885CHRM2 701/4885 |
| US-20110015404-A1 | Electroluminescent Materials | ZYX, FLNB, LMNB2 | CYP1A2 2211/4885HIF1A 4225/4885CHRM2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.